A virosomal formulated Her-2/neu multi-peptide vaccine induces Her-2/neu-specific immune responses in patients with metastatic breast cancer: A phase i study

Breast Cancer Research and Treatment

Volumn 119, Issue 3, 2010, Pages 673-683

  Wiedermann, Ursula ^a   Wiltschke, C ^b   Jasinska, J ^a,e   Kundi, M ^b   Zurbriggen, R ^c   Garner Spitzer, E ^a   Bartsch, R ^b   Steger, G ^b   Pehamberger, H ^d,e   Scheiner, O ^a,e   Zielinski, C C ^b,e  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c Pevion Biotech Ltd   (Switzerland)

^d Universitatsklinik fur Dermatologie   (Austria)

^e BioLife Science   (Austria)

Author keywords

Antibodies; B cell peptides; Her 2 neu; Phase I trial; T cell; T regulatory cells; Vaccination; Virosomes

Indexed keywords

ANASTROZOLE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EXEMESTANE; FULVESTRANT; GAMMA INTERFERON; INTERLEUKIN 2; NEUTRALIZING ANTIBODY; PEV6; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIROSOME VACCINE;

ADULT; AGED; ANTIBODY TITER; ARTICLE; BREAST CANCER; CARDIOTOXICITY; CD4+ CD25+ T LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOHISTOCHEMISTRY; IMMUNOLOGICAL TOLERANCE; INFLUENZA; INJECTION SITE ERYTHEMA; LIVER TOXICITY; METASTASIS; NEPHROTOXICITY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANTIBODIES, NEOPLASM; ANTIGENS, NEOPLASM; B-LYMPHOCYTE SUBSETS; BLOTTING, WESTERN; BREAST NEOPLASMS; CANCER VACCINES; CELL SEPARATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES, B-LYMPHOCYTE; FEMALE; FLOW CYTOMETRY; HUMANS; MIDDLE AGED; RECEPTOR, ERBB-2; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY; VACCINES, SUBUNIT; VACCINES, VIROSOME;

EID: 74849113525     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-009-0666-9     Document Type: Article

References (37)

1. DJ Slamon GM Clark SG Wong WJ Levin A Ullrich WL McGuire 1987 Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 235 4785 177 182 10.1126/science.3798106 1:CAS:528:DyaL2sXhtVSht7s%3D 3798106
2. IL Andrulis SB Bull ME Blackstein, et al. 1998 neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group J Clin Oncol 16 4 1340 1349 1:STN:280:DyaK1c3htFOlsw%3D%3D 9552035
3. TM Suter M Procter DJ van Veldhuisen, et al. 2007 Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial J Clin Oncol 25 25 3859 3865 10.1200/JCO.2006.09.1611 1:CAS:528:DC%2BD2sXhtFanu7zE 17646669 (Pubitemid 47477261)
4. DG Maloney AJ Grillo-Lopez DJ Bodkin, et al. 1997 IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma J Clin Oncol 15 10 3266 3274 1:CAS:528:DyaK2sXmslOlu7g%3D 9336364
5. CL Vogel MA Cobleigh D Tripathy, et al. 2002 Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer J Clin Oncol 20 3 719 726 10.1200/JCO.20.3.719 1:CAS:528:DC%2BD38XhsVGmt7o%3D 11821453 (Pubitemid 34111379)
6. SA Rosenberg JC Yang NP Restifo 2004 Cancer immunotherapy: moving beyond current vaccines Nat Med 10 9 909 915 10.1038/nm1100 1:CAS:528: DC%2BD2cXntFSktL0%3D 15340416 (Pubitemid 39273730)
7. PL Lollini F Cavallo P Nanni G Forni 2006 Vaccines for tumour prevention Nat Rev Cancer 6 3 204 216 10.1038/nrc1815 1:CAS:528:DC%2BD28Xhsleltrk%3D 16498443 (Pubitemid 43292564)
8. J Jasinska S Wagner C Radauer, et al. 2003 Inhibition of tumor cell growth by antibodies induced after vaccination with peptides derived from the extracellular domain of Her-2/neu Int J Cancer 107 6 976 983 10.1002/ijc.11485 1:CAS:528:DC%2BD3sXptFOgtb4%3D 14601058 (Pubitemid 37429840)
9. S Wagner J Jasinska H Breiteneder M Kundi H Pehamberger O Scheiner CC Zielinski U Wiedermann 2007 Delayed tumor onset and reduced tumor growth progression after immunization with a Her-2/neu multi-peptide vaccine and IL-12 in c-neu transgenic mice Breast Cancer Res Treat 106 1 29 38 10.1007/s10549-006-9469-4 1:CAS:528:DC%2BD2sXhtFSmu7rJ 17203384 (Pubitemid 47498086)
10. R Zurbriggen 2003 Immunostimulating reconstituted influenza virosomes Vaccine 21 9-10 921 924 10.1016/S0264-410X(02)00541-8 1:CAS:528: DC%2BD3sXltlSnsw%3D%3D 12547603 (Pubitemid 36126427)
11. PA Bovier 2008 Epaxal: a virosomal vaccine to prevent hepatitis A infection Expert Rev Vaccines 7 8 1141 1150 10.1586/14760584.7.8.1141 1:CAS:528:DC%2BD1cXht1Glu7jE 18844588
12. FM Thompson DW Porter SL Okitsu, et al. 2008 Evidence of blood stage efficacy with a virosomal malaria vaccine in a phase IIa clinical trial PLoS ONE 3 1 e1493 10.1371/journal.pone.0001493 18231580 (Pubitemid 351827205)
13. E Garner-Spitzer M Kundi P Rendi-Wagner, et al. 2009 Correlation between humoral and cellular immune responses and the expression of the hepatitis A receptor HAVcr-1 on T cells after hepatitis A re-vaccination in high and low-responder vaccinees Vaccine 27 2 197 204 10.1016/j.vaccine.2008.10.045 1:CAS:528:DC%2BD1cXhsV2gurfJ 18996424
14. CA Phillips BR Forsyth WA Christmas DW Gump EB Whorton I Rogers A Rudin 1970 Purified influenza vaccine: clinical and serologic responses to varying doses and different routes of immunization J Infect Dis 122 1 26 32 1:STN:280:DyaE3c3ltlWqtw%3D%3D 5433710
15. CC Zielinski I Stuller F Dorner P Potzi C Muller MM Eibl 1986 Impaired primary, but not secondary, immune response in breast cancer patients under adjuvant chemotherapy Cancer 58 8 1648 1652 10.1002/1097-0142(19861015)58: 8<1648::AID-CNCR2820580812>3.0.CO;2-E 1:STN:280:DyaL2s%2FgtF2iug%3D%3D 3019506
16. JW Molling W Kolgen HJ van der Vliet, et al. 2005 Peripheral blood IFN-gamma-secreting Valpha24+Vbeta11+NKT cell numbers are decreased in cancer patients independent of tumor type or tumor load Int J Cancer 116 1 87 93 10.1002/ijc.20998 1:CAS:528:DC%2BD2MXls1Kjt78%3D 15756674 (Pubitemid 40827759)
17. UK Liyanage TT Moore HG Joo, et al. 2002 Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma J Immunol 169 5 2756 2761 1:CAS:528: DC%2BD38XmsF2ns7k%3D 12193750
18. B Fisk TL Blevins JT Wharton CG Ioannides 1995 Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines J Exp Med 181 6 2109 2117 10.1084/jem.181.6.2109 1:CAS:528:DyaK2MXlvFSjtLY%3D 7539040
19. ML Disis KH Grabstein PR Sleath MA Cheever 1999 Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine Clin Cancer Res 5 6 1289 1297 1:CAS:528: DyaK1MXkt1Oqur0%3D 10389911
20. ML Disis JR Gralow H Bernhard SL Hand WD Rubin MA Cheever 1996 Peptide-based, but not whole protein, vaccines elicit immunity to HER-2/neu, oncogenic self-protein J Immunol 156 9 3151 3158 1:CAS:528:DyaK28XisFaqsrY%3D 8617935
21. S Matsui JD Ahlers AO Vortmeyer M Terabe T Tsukui DP Carbone LA Liotta JA Berzofsky 1999 A model for CD8+ CTL tumor immunosurveillance and regulation of tumor escape by CD4 T cells through an effect on quality of CTL J Immunol 163 1 184 193 1:CAS:528:DyaK1MXkt1ShtL4%3D 10384115
22. MJ Welters GG Kenter SJ Piersma, et al. 2008 Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine Clin Cancer Res 14 1 178 187 10.1158/1078-0432.CCR-07-1880 1:CAS:528:DC%2BD1cXoslGh 18172269
23. GE Peoples JP Holmes MT Hueman, et al. 2008 Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02 Clin Cancer Res 14 3 797 803 10.1158/1078-0432.CCR- 07-1448 1:CAS:528:DC%2BD1cXhsFykt7o%3D 18245541 (Pubitemid 351231162)
24. K Hung R Hayashi A Lafond-Walker C Lowenstein D Pardoll H Levitsky 1998 The central role of CD4(+) T cells in the antitumor immune response J Exp Med 188 12 2357 2368 10.1084/jem.188.12.2357 1:CAS:528:DyaK1MXhtFejtw%3D%3D 9858522 (Pubitemid 29028508)
25. V Kunzi M Dornseiff J Horwath K Hartmann 2009 Safe vaccination of children with a virosomal adjuvanted influenza vaccine Vaccine 27 8 1261 1265 10.1016/j.vaccine.2008.12.008 1:CAS:528:DC%2BD1MXhtlSnt7g%3D 19114080
26. AL Coveler V Goodell DJ Webster LG Salazar PA Fintak JS Childs DM Higgins ML Disis 2009 Common adjuvant breast cancer therapies do not inhibit cancer vaccine induced T cell immunity Breast Cancer Res Treat 113 1 95 100 10.1007/s10549-008-9910-y 1:CAS:528:DC%2BD1cXhsFWrs7nI 18236151
27. ML Disis V Goodell K Schiffman KL Knutson 2004 Humoral epitope-spreading following immunization with a HER-2/neu peptide based vaccine in cancer patients J Clin Immunol 24 5 571 578 10.1023/B:JOCI.0000040928.67495.52 1:CAS:528:DC%2BD2cXnsVWqsLg%3D 15359116 (Pubitemid 39221675)
28. D Goldblatt AR Vaz E Miller 1998 Antibody avidity as a surrogate marker of successful priming by Haemophilus influenzae type b conjugate vaccines following infant immunization J Infect Dis 177 4 1112 1115 10.1086/517407 1:STN:280:DyaK1c7psVKiug%3D%3D 9534995
29. G Pfister D Weiskopf L Lazuardi, et al. 2006 Naive T cells in the elderly: are they still there? Ann N Y Acad Sci 1067 152 157 10.1196/annals.1354.018 1:CAS:528:DC%2BD28Xms1OksL4%3D 16803980 (Pubitemid 43806319)
30. C Horlock B Stott PJ Dyson M Morishita RC Coombes P Savage J Stebbing 2009 The effects of trastuzumab on the CD4+CD25+FoxP3+ and CD4+IL17A+ T-cell axis in patients with breast cancer Br J Cancer 100 7 1061 1067 10.1038/sj.bjc.6604963 1:CAS:528:DC%2BD1MXktVGktrg%3D 19277040
31. Y Mizukami K Kono Y Kawaguchi H Akaike K Kamimura H Sugai H Fujii 2008 Localisation pattern of Foxp3+ regulatory T cells is associated with clinical behaviour in gastric cancer Br J Cancer 98 1 148 153 10.1038/sj.bjc.6604149 1:CAS:528:DC%2BD1cXisF2rsg%3D%3D 18087278
32. K Kono H Kawaida A Takahashi H Sugai K Mimura N Miyagawa H Omata H Fujii 2006 CD4(+)CD25 high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers Cancer Immunol Immunother 55 9 1064 1071 10.1007/s00262-005-0092-8 1:CAS:528:DC%2BD28XkvFOjurY%3D 16328385 (Pubitemid 43800721)
33. L Vence AK Palucka JW Fay T Ito YJ Liu J Banchereau H Ueno 2007 Circulating tumor antigen-specific regulatory T cells in patients with metastatic melanoma Proc Natl Acad Sci USA 104 52 20884 20889 10.1073/pnas.0710557105 1:CAS:528:DC%2BD1cXkt1Gqtw%3D%3D 18093940
34. K Enarsson A Lundgren B Kindlund M Hermansson G Roncador AH Banham BS Lundin M Quiding-Jarbrink 2006 Function and recruitment of mucosal regulatory T cells in human chronic Helicobacter pylori infection and gastric adenocarcinoma Clin Immunol 121 3 358 368 10.1016/j.clim.2006.07.002 1:CAS:528: DC%2BD28Xht1Cis77J 16934529 (Pubitemid 44738715)
35. D Generali G Bates A Berruti, et al. 2009 Immunomodulation of FOXP3+ regulatory T cells by the aromatase inhibitor letrozole in breast cancer patients Clin Cancer Res 15 3 1046 1051 10.1158/1078-0432.CCR-08-1507 1:CAS:528:DC%2BD1MXht1Onsrg%3D 19188178
36. ML Disis K Schiffman K Guthrie LG Salazar KL Knutson V Goodell C dela Rosa MA Cheever 2004 Effect of dose on immune response in patients vaccinated with an her-2/neu intracellular domain protein-based vaccine J Clin Oncol 22 10 1916 1925 10.1200/JCO.2004.09.005 1:CAS:528:DC%2BD2cXptlCksrk%3D 15143085 (Pubitemid 41095184)
37. JP Holmes JD Gates LC Benavides, et al. 2008 Optimal dose and schedule of an HER-2/neu (E75) peptide vaccine to prevent breast cancer recurrence: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02 Cancer 113 7 1666 1675 10.1002/cncr.23772 1:CAS:528:DC%2BD1cXht1Ggu7bK 18726994